• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    L

    Lankenau Medical Center,Main Line Health

    EST. 1850
    891论文总数
    2.5万引用总数

    Lankenau Medical Center, part of Main Line Health, is a 370-bed acute care, teaching hospital in Wynnewood, Lower Merion Township, Pennsylvania. Lankenau Medical Center has been named as one of the top 5 hospitals in the Philadelphia region by U.S. News & World Report and received the Gold Seal of Approval from the Joint Commission. Lankenau Medical Center’s clinical areas include the Lankenau Heart Institute, the gastrointestinal and GI endoscopy program, cancer care services, pulmonology, orthopaedics, obstetrics and maternity, including and a level III neonatal intensive care unit, as well as minimally invasive and robotic surgery. The campus is also home to the Lankenau Institute for Medical Research and the Annenberg Center for Medical Education.

    论文量&引用量时间轴

    机构学者

    论文(891)

    年份
    起
    –
    止
    排序
    1Mechanism of Mortality in Individuals with Elevated Risk Pulmonary Emboli: A Multicenter Analysis of a Contemporary Cohort
    Zach Rozenbaum,Eric Gnall,Ali Gholam, Mailing Flores Chang, Aabha Divya,Cristina Sanina,Jose Wiley

    Background The underlying causes of mortality in patients with pulmonary embolism have been investigated in the past, yet management of pulmonary emboli has evolved and newer therapeutic options are available. Methods Data from four hospitals during 2022-2025 were analyzed and all patients with intermediate-high risk and high risk pulmonary emboli who died during follow up were included. Results The main cause of mortality in intermediate-high risk PE was unrelated to the PE, contrasting that of high-risk PE. Almost 90% of deaths in patients with high-risk PE occurred during the index hospitalization, whereas intermediate-high-risk PE occurred after discharge. Notably, 11% of the subjects in the cohort had intra-procedural thrombectomy mortality. Conclusions The results depicted in the research letter provide insight into the mechanism of morality in patients with pulmonary emboli by risk category and thereby help improve care and patient selection for interventions.

    2027American Heart Journal(2027)
    引用
    AI阅读
    加入学术空间
    2Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: the TRISCEND II Trial.
    Philipp Lurz,Rebecca T Hahn,Susheel Kodali,Raj Makkar,Rahul P Sharma,Charles J Davidson, Brian P O'Neill,Pradeep Yadav,Firas Zahr,Scott Chadderdon,Mackram F Eleid,Molly Szerlip,

    BACKGROUND AND AIMS:The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. METHODS:The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan-Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. RESULTS:One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (-11.6, 11.9), massive/torrential -5.8% (-17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (-3.0, 22.7), massive/torrential -15.2% (-28.9, -1.5)]. CONCLUSIONS:Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.

    2026European heart journal(2026)引用:9
    引用
    AI阅读
    加入学术空间
    3Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial
    D. R. Holmes, S. Manoian, R. Layeequr Rahman, R. C. Ward, N. Z. Carp, M. Plaza, K. Kozlowski, S. Abe, L. Bailey, L. Kruper, V. Jones, S. Patterson,

    Cryoablation is emerging as a minimally invasive alternative to lumpectomy for select women with early-stage breast cancer. The FROST trial (NCT01992250) was a prospective, phase 2 multicenter study evaluating the outcome of cryoablation in the management of stage I, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative invasive ductal carcinoma. Women 50 years old or older with unifocal, ultrasound-visible tumors were stratified by age: stratum 1 (age ≥70 years, endocrine therapy only) and stratum 2 (age 50–69 years, endocrine therapy + radiotherapy + optional sentinel node biopsy). Cryoablation was performed using a single cryoprobe under ultrasound guidance. Core biopsy 6 months after ablation was performed to confirm complete ablation. Patients were followed with clinical exams and imaging. The study included 83 completed cryoablations and follow-up evaluations. The median tumor size was 9 mm. More than 85

    2026Annals of Surgical Oncology(2026)引用:4
    引用
    AI阅读
    加入学术空间
    4Safety and Feasibility of Left Bundle Branch Area Pacing Following Transcatheter Tricuspid Valve Replacement.
    Mohammed Kamareddine, Farah Olleik, Colleen Hanley, Scott Goldman,William A Gray,Ali Keramati

    BACKGROUND:Transcatheter tricuspid valve replacement (TTVR) is a novel therapy for severe tricuspid regurgitation. However, conduction disturbances requiring pacemaker implantation occur in up to 24.7% of patients. Left bundle branch area pacing (LBBAP) has not been systematically evaluated post-TTVR, where lead passage across the prosthesis may compromise valve integrity. The objective of this paper was to report the feasibility, safety, and performance of LBBAP after TTVR. CASE SUMMARY:Two pacemaker-naïve patients requiring pacing post-TTVR were retrospectively analyzed. DISCUSSION:Both patients underwent TTVR and developed high-grade atrioventricular block within 72 hours. LBBAP was successful in both cases with no procedural-related complications. At 30 days, pacing parameters remained unchanged with no device-related adverse events. Echocardiography at 1 and 30 days demonstrated ≤ mild tricuspid regurgitation, no lead-valve interaction, and stable right ventricular function. TAKE-HOME MESSAGES:LBBAP post-TTVR is feasible with excellent short-term safety and performance while maintaining valve integrity. Our series reinforces its safety and adds systematic echocardiographic follow-up.

    2026JACC Case reports(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Long-term Results of the North American Phase II Transanal Total Mesorectal Excision Multicenter Trial for Rectal Cancer.
    Katherine F Donovan,Heather Carmichael,Sami Chadi,Alison Ricardo,Antoinette Bonaccorso,Elisa Paoluzzi Tomada,Dana Sands,John Marks, Justin Maykel,Karim Alavi,Karen Zaghiyan,Mark Whiteford,

    BACKGROUND:Transanal total mesorectal excision (taTME) facilitates sphincter preservation in low rectal cancer. Preliminary results and functional outcomes from the North American multicenter phase II taTME trial (NCT03144765) have been published. Three-year outcomes are reported. METHODS:Patients with stage I to III rectal adenocarcinoma were enrolled across 11 centers (2017-2022). Endpoints included TME grade, 3-year overall survival, disease-free survival, cancer-specific survival, recurrence, late (beyond 90 d) complications, and stoma-free survival. Surveillance followed National Comprehensive Cancer Network guidelines, with pelvic magnetic resonance imaging (MRI) at 3 years to assess for pelvic sidewall recurrence when possible. Kaplan-Meier analysis assessed oncologic outcomes. RESULTS:One hundred patients underwent taTME for tumors at a median of 5.8 cm from the anal verge, with intersphincteric resection in 36% and handsewn anastomosis in 54%. Median follow-up was 50.9 months. Late complications occurred in 32 patients, including 21 severe (Clavien-Dindo ≥3). Late anastomotic complications occurred in 5 patients; one required surgical revision. Estimated 3-year overall survival, cancer-specific survival, and disease-free survival were 93.7%, 96.6%, and 84.6%, respectively. Distant recurrence occurred in 15 patients (median: 17.6 months), most commonly in the lung and liver. Locoregional recurrence occurred in 2 patients. Preoperative N stage, lymph node yield, tumor deposits, and perineural invasion were associated with recurrence. Among 100 patients diverted at taTME, 97% were stoma-free at 3 years; 4 patients later underwent secondary diversion. CONCLUSIONS:Three-year outcomes of this multicenter trial support the safety and efficacy of taTME in resectable mid and low rectal tumors, with outcomes comparable to contemporary studies. Longer-term oncologic and functional outcomes are needed.

    2026Annals of surgery(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 891 篇论文

    合作机构(100)

    兰肯瑙医学研究所合作论文 104
    宾夕法尼亚大学合作论文 46
    托马斯杰斐逊大学合作论文 46
    哥伦比亚大学合作论文 43
    华盛顿大学合作论文 26
    杜克大学合作论文 23
    Philadelphia College of Osteopathic Medicine合作论文 23
    斯坦福大学合作论文 22
    西北大学合作论文 21
    Main Line Health合作论文 20

    机构统计